MASH / NASH
The MASH / NASH pipeline: 36 tracked drugs, 2 approved for this indication.
2 approved / phase 47 Phase 31 Phase 2/318 Phase 21 Phase 1/22 Phase 15 preclinical / unstaged
Compare the share prices of listed companies in MASH / NASH →
Total attributable cost
$32.0B
$2,150/patient
Drug spend
Not yet sourced
All diagnosed and undiagnosed adult MASH/NASH severity strata (US estimate; upper-bound prevalence context) · US
The MASH / NASH pipeline
Key trial results for every approved and late-stage drug: MASH / NASH results by drug.